On January 13, 2015, Huanyu Dakang Medical News pharmaceutical giant Squibb Company ushered in a good start in 2015. The anti-cancer immunotherapy drug nivolumab developed by the company was approved last month under the trade name of Opdivo. In the first month of 2015, Opdivo heard good news again. In a comparative clinical study of የሳምባ ካንሰር conducted by Squibb, Opdivo obtained new positive research data. In this clinical study involving 272 lung cancer patients, the researchers compared the efficacy of Opdivo with the current clinical standard therapy docetaxel, and the results proved the obvious advantage of this drug in the overall survival rate of patients. Reached the primary end point expected by previous researchers.
Opdivo is currently the most popular PD-1 drug. PD-1 is a cell cycle checkpoint protein. Its runaway causes እብጠት cells to escape immune monitoring in the body. According to the decision made by the FDA last month, Opdivo was approved for the treatment of ሜላኖማ (related reading: FDA approved Squibb PD-1 inhibitor Nivolumab (Opdivo) three months in advance, the same price as Keytruda) Similar drugs in this field are Keytruda from Merck. The results of Squibb ’s clinical research have made Opdivo the first PD-1 drug to treat lung cancer. More importantly, this result will help Squibb to lead its competitors in PD-1 drug research. Pharmaceutical companies currently active in this area include biomedical giants such as Merck, Roche and AstraZeneca.
Squibb ኩባንያው ለኤፍዲኤ እና ለአውሮፓ ህብረት የመድኃኒት አስተዳደር የ Opdivo የሳንባ ካንሰር ምልክቶችን ለማከም ማመልከቻ እንዳቀረበ ገልጿል። እርግጥ ነው፣ የሥልጣን ጥመኛው ስኩዊብ ኩባንያ በተፈጥሮ በሳንባ ካንሰርና በሜላኖማ ብቻ አይረካም። በእርግጥ ስኩዊብ በአሁኑ ጊዜ ከ 35 በላይ ጥናቶችን በኦፕዲቮ ብቻ ወይም ከሌሎች መድሃኒቶች ጋር በማጣመር የተለያዩ ዕጢዎችን ለማከም እያደረገ ነው. እንደ ተንታኞች ከሆነ የኦፒዲቮ የወደፊት ሽያጭ እስከ 5 ቢሊዮን ዶላር ይደርሳል።
The cancer immunotherapy research that has emerged in recent years has brought new hope for humans to conquer the disease of cancer. Almost all biomedical giants are planning in this field, hoping to share a cake. However, it is not yet known who will be the biggest winner in this technological revolution.
ዝርዝር የእንግሊዝኛ ዘገባ፡-
የብሪስቶል-ማየርስ ስኩዊብ ($ ኪዩብ) የቆመ ኢሚውኖ-ኦ ንኮሎጂ መድሀኒት ኒቮሉማብ ባለፈው ወር የጸደቀው እንደ ኦፕዲቮ በኋለኛው ደረጃ የሳንባ ካንሰር ሙከራ ላይ አስደናቂ ስኬት አስመዝግቧል፣ ይህም ለፒዮ ኒሪንግ ህክምና የሚጠበቀውን የሽያጭ መጠን ያጠናክራል።
በ272-ታካሚዎች ጥናት ኦፒዲቮን ከመደበኛው የካንሰር ገዳይ ዶሴታክስል ጋር በማጋጨት፣ የብሪስቶል-ማየርስ መድሀኒት ማሳያ ከጋራ ተቆጣጣሪው ክንድ ጋር ሲወዳደር የላቀ አጠቃላይ ህልውናን አሳይቷል እናም ከታቀደው ጊዜ በፊት ዋና የመጨረሻ ነጥቡን በመምታት የሙከራውን መረጃ በመምራት ኮሚቴው ይመክራል። ጥናቱ ቀደም ብሎ ይቋረጣል. ብሪስቶል-ማየርስ አሁን በዶሴታክስል ቡድን ውስጥ ያሉትን ታካሚዎች በክፍት መለያ ማራዘሚያ ጥናት ወደ ኦፕዲቮ እንዲመርጡ እየጋበዘ ነው።
የብሪስቶል-ማየርስ ሕክምና PD-1 የተባለውን መንገድ በመዝጋት በዕጢዎች ላይ የሚደርሰውን በሽታ የመከላከል ሥርዓት ለማበረታታት የተነደፈ ሲሆን ይህም ቁጥጥር ሳይደረግበት የካንሰር ሕዋሳት በሰውነት ተፈጥሯዊ መከላከያ ሳይታወቅ እንዲያልፍ ያስችላል። ልክ እንደ Merck's ($ MRK) ተመሳሳይ Keytruda፣ Opdivo ባለፈው አመት ለሜላኖማ ሕክምና ተብሎ የኤፍዲኤ ይሁንታን አሸንፏል፣ ነገር ግን የብሪስቶል-ማየርስ መድሀኒት በሳንባ ካንሰር ብቻውን ይቆማል። ከበሽታው የመዳን ጥቅም እንዳለው ኩባንያው ገልጿል።
Opdivo’s particular promise in አነስተኛ ያልሆነ ህዋስ ሳንባ ካንሰር has led analysts to pencil it in as the most commercially promising among therapies that block PD-1 and the related PD-L1, putting Bristol-Myers ahead of Merck, Roche ($ RHHBY), AstraZeneca ($ AZN) and others. Analysts figure Opdivo will bring in peak sales of around $ 5 billion, and Leerink’s Seamus Fernandez believes the treatment’s potential in lung cancer will take it as high as $ 7.3 billion by 2020. The entire class of therapies is expected to bring in a bout $ 35 billion a year.
ብሪስቶል-ማየርስ በዚህ አመት መጨረሻ ላይ የመድኃኒቱን አጠቃቀም እንደሚያሰፋ በመጠበቅ በአሜሪካ እና በአውሮፓ ለኦፕዲቮ በሳንባ ካንሰር የሳንባ ካንሰር ማመልከቻዎችን አቅርቧል።
Like its competitors, Bristol-Myers has mounted an expansive R & D program for its PD-1 candidate, running more than 35 trials in total that test Opdivo alone or as part of a cocktail in renal cell carcinoma, የጭንቅላት እና የአንገት ካንሰር, glioblastoma, Non-Hodgkin lymphoma and other cancers.
